Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | UTS2R | Q9UKP6 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15547138 | 0.91 | MEN1 (0.47) | MEN1KMT2ARXFP1UTS2RHPGD | |
| SCHEMBL16907796 | 0.91 | MEN1 (0.47) | MEN1KMT2ARXFP1UTS2RTP53 | |
| SCHEMBL16893373 | 0.91 | MEN1 (0.52) | MEN1KMT2ARXFP1HPGDTP53 | |
| SCHEMBL15547238 | 0.90 | MEN1 (0.56) | MEN1KMT2ARXFP1HPGDTP53 | |
| SCHEMBL16893414 | 0.89 | MEN1 (0.46) | MEN1KMT2ARXFP1UTS2RTP53 | |
| SCHEMBL16893415 | 0.89 | MEN1 (0.46) | MEN1KMT2ARXFP1UTS2RTP53 | |
| SCHEMBL16893486 | 0.88 | MEN1 (0.57) | MEN1KMT2ARXFP1HPGDTP53 | |
| SCHEMBL15546901 | 0.85 | MEN1 (0.59) | MEN1KMT2ARXFP1HPGDTP53 | |
| SCHEMBL16893430 | 0.84 | KMT2A (0.52) | MEN1KMT2ARXFP1HPGDTP53 | |
| SCHEMBL15545878 | 0.82 | RXFP1 (0.75) | MEN1KMT2ARXFP1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | claimed |
| EP-2875010-B1 | THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-08-31 | — | — | EP | claimed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | claimed |
| CN-104718200-A | Thiophene derivatives used in the treatment of diabetes | METABRAIN RES | 2015-06-17 | — | — | CN | claimed |
| EP-2875010-A1 | THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES | Metabrain Research (FR) | 2015-05-27 | — | — | EP | claimed |
| WO-2014013181-A1 | THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2014-01-23 | — | — | WO | claimed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| EP-2875010-B1 | THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-08-31 | — | — | EP | disclosed |
| EP-2875010-B1 | THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-08-31 | — | — | EP | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| CN-104718200-A | Thiophene derivatives used in the treatment of diabetes | METABRAIN RES | 2015-06-17 | — | — | CN | disclosed |
| EP-2875010-A1 | THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES | Metabrain Research (FR) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014013181-A1 | THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | SLC5A2, SLC5A1, TPMT | MEN1 4184/4885KMT2A 4602/4885RXFP1 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.